These combined with anti-HER2 therapy was a feasible option for treating patients with HER2-positive GC based on the synergistic mechanism of anti-HER2 therapy and PD-1 inhibitors (Yamashita et al., 2021). Here, ERBB2 is linked to gastric cancer.